DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Author(s): Mbawuike I, Zang Y, Couch RB

Affiliation(s): Baylor College of Medicine, Department of Molecular Virology & Microbiology, One Baylor Plaza, MS: BCM280, Houston, TX 77030, USA. Mbawuike@bcm.tmc.edu

Publication date & source: 2007-04-30, Vaccine., 25(17):3263-9. Epub 2007 Jan 24.

Publication type: Randomized Controlled Trial; Research Support, N.I.H., Extramural

To evaluate humoral (antibody) and cell mediated immune (CMI) responses, 30 healthy young adults were either given inactivated influenza vaccine with or without QS21 adjuvant. Vaccination site pain and postvaccination myalgias were greater in the QS21 group. Serum antibody increases occurred in 73-93% of subjects for each vaccine and antigen at 2 weeks and 4 weeks but frequencies and mean titers for the two vaccines were not different. No differences in T cell cytotoxicity were detected for either vaccine for influenza A or B infected cells. IFN-gamma for both vaccine groups was increased in supernates after 3 days but not 7 days of stimulation in the cytotoxicity tests; amounts for the two vaccines were similar. To further evaluate CMI, remaining PBMCs were stimulated overnight with cells infected with each vaccine strain; an increase in spot forming cells (sfc) for Granzyme B and IFN-gamma was found for all subjects and in 51 of 54 sfc tests. A slightly higher response in the Gran B test for QS21 subjects was suggested, but no clear immune response advantage was identified among healthy adults for QS21 adjuvanted influenza vaccine.

Page last updated: 2007-06-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017